Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag UAE approves gene therapy for spinal muscular atrophy in children age 2 and up.

flag The UAE has approved Itvisma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA), for patients aged two and older, becoming the second country globally to do so. flag The Emirates Drug Establishment (EDE) granted approval based on clinical evidence showing sustained motor function improvements and a favorable safety profile. flag The treatment uses an adeno-associated viral vector to replace the defective gene causing SMA. flag EDE officials highlighted the UAE’s efficient, science-driven regulatory process, balancing speed, rigor, and transparency. flag The move supports the UAE’s vision for a sustainable, knowledge-driven healthcare system and strengthens its role as a regional hub for medical innovation. flag Novartis, the manufacturer, praised the approval as a step toward equitable access to breakthrough therapies for rare genetic diseases.

7 Articles

Further Reading